177 results
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive … -rated for services rendered) and annual bonus targets ranging from 30% to 40%. They also provide for long-term incentives in the form of equity awards
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
believes will be first-in class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality … $175,000 to $348,000 (pro-rated for services rendered) and annual bonus targets ranging from 30% to 40%. They also provide for long-term incentives
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive cancers.
Our access … marketplace and explore the potential to further enhance long-term clinical benefits for patients with cancer and also expand the eligible population
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive cancers. Portage’s … for services rendered) and annual bonus targets ranging from 30% to 40%. They also provide for long-term incentives in the form of equity awards from time
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Nov 23
Current report (foreign)
4:01pm
provide for long-term incentives in the form of equity awards from time to time under the Portage Biotech Inc. Amended and Restated 2021 Equity Incentive … on April 23, 2021.
Portage is a clinical-stage immuno-oncology company advancing therapies that target known checkpoint resistance pathways to improve long
6-K
EX-99.2
bqi no1il4ze
28 Nov 23
Current report (foreign)
4:01pm
424B3
c9m2ezf73xvk
7 Nov 23
Prospectus supplement
4:50pm
F-1
acc1jjsdk d2a9cgh
31 Oct 23
Registration statement (foreign)
4:05pm
424B5
un6miexvrqw94c be
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.2
q1mps6j5k nmcu
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
uysaipjpc2lshoy4w xw
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
p8teyg2uz5fvs3eeev3
31 Jul 23
Current report (foreign)
6:10pm
6-K
EX-99.2
gsr7l8iui4tojfs
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.1
qqmuweo0g7vujibhz e5
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.1
7bgxk
9 Nov 22
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
4:01pm
6-K/A
EX-99.3
k918 ruulf34o
12 Oct 22
Financial Statements for the years ended Report of Independent Registered Public Accounting Firm
5:45pm
6-K
EX-99.1
ykssd3corix gz
29 Aug 22
Current report (foreign)
4:00pm
424B5
fmm9 kg1h
19 Aug 22
Prospectus supplement for primary offering
10:52am